Phytoestrogens of Pachyrhizus erosus prevent Bone Loss in an Ovariectomized Rat Model of Osteoporosis

Authors

  • Arief Nurrochmad Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Gadjah Mada University, Sekip Utara Yogyakarta 55281, Indonesia.
  • Fransiska Leviana Faculty of Pharmacy, Setia Budi University, Jl. Letjen Sutoyo Mojosongo, Surakarta 57127, Indonesia
  • Caecilia Govita Wulancarsari Cancer Chemopreventive Research Center, Faculty of Pharmacy, Gadjah Mada University, Sekip Utara Yogyakarta 55281, Indonesia.
  • Endang Lukitaningsih Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gadjah Mada University, Sekip Utara Yogyakarta 55281, Indonesia.

Keywords:

phytoestrogen, Pachyrhizus erosu, ovariectomizedrat, osteoporosis

Abstract

The effects of the etyl acetate extract of root of Pachyrhizus erosus (L) Urb (EPE) on bone loss and in ovariectomized (ovx) rats model of osteoporosis were investigated. Forty-two 6-weeksold female Sprague–Dawley rats were randomly assigned to six groups as followed, sham-operated, OVX, OVX-Estradiol (2 μg/day), OVX-EPE 200 mg/kg BW, OVX-EPE 400 mg/kg BW, OVX-EPE 800 mg/kg BW for 4 weeks. The administration of EPE was given orally using a stomach tube. The results demonstrated that the administration EPE 200, 400, and 800 mg/kg BW significantly prevented bone loss in OVX rats which these effect equivalent to estradiol. These effects were described in increased length of femur and tibiae, bone density, and mineral content of calcium and phosphorous in bone ash. EPE also significantly prevented OVX-induced uterine atrophy and increased in body weight gain. The femur mechanical testing significantly increased the ultimate load and stiffness of femurs of ovariectomized-rats that its effect was greater than OVX or shamoperated rats. Increased bone density may lead to enhanced bone strength, reducing the risk of fracture, which is evident in the administration of EPE due to high content of mineral density and content and increase the ultimate load. This effect seems to be pro-estrogenic compound, which suppress bone resorption by directly acting on estrogen receptor in bone sites. This study suggest that phytoestrogen compound from Pachyrhizus erosus may offer a potential alternative therapy for the treatment of health problems such as osteoporosis in post-menopausal women.

References

Maggi S, Kelsey JL, Litvak J, Heyse SP.

Incidence of hip fractures in the elderly: a

cross-national analysis. Osteoporos Int

;1:232–41.

Ross PD, Fujiwara S, Huang C, Davis JW,

Epstein RS, Wasnich RD, Kodama K,

Melton LJ Vertebral fracture prevalence in

women in Hiroshima compared to Caucasian

or Japanese in the US. Inc J Epidemiol

;24:1171–1177.

Lau EMC, Cooper C. The epidemiology of

osteoporosis: the oriental perspective in a

world context. Clin Orthop 1996; 323:65–74.

Lindsay R, Hart DM, Aitken JM, MacDonald

ED, Anderson JB, Clarke AC. Long-term

prevention of postmenopausal osteoporosis

by oestrogen. Lancet 1976;1:1038–1041.

Lindsay R, Hart DM, Clark DM. The

minimum effective dose of estrogen for

prevention of postmenopausal bone loss.

Obstet Gynecol 1984;63:759–763.

Gordon GS, Picchi J, Roof BS. Antifracture

efficacy of long-term oestrogens for

osteoporosis. Trans Assoc Am Physicians

;86: 326–331.

Hutchinson TA, Polansky SM, Feinstein AP.

Postmenopausal oestrogens protect against

fractures of hip and distal radius. Lancet

;2:706–709.

Michaëlsson K, Baron JA, Farahmand BY,

Johnell O, Magnusson C, Persson PG,

Persson I, Ljunghall S. Hormone

replacement therapy and risk of hip fracture:

population based case-control study. The

Swedish Hip Fracture Study Group. BMJ

;316:1858–1863.

Blank RD, Bockman RS. A review of clinical

trials of therapies for osteoporosis using

fracture as an end point. J Clin Densitom

;2: 435–452.

Writing Group for the Women’s Health

Initiative Investigators. Risks and benefits of

estrogen plus progestin in healthy

postmenopausal women: principal results

from the Women’s Health Initiative

randomized controlled trial. JAMA

;288:321–333.

Lacey JV Jr, Mink PJ, Lubin JH, Sherman

ME, Troisi R, Hartge P, Schatzkin A,

Schairer C. Menopausal hormone

replacement therapy and the risk of ovariacancer. JAMA 2002;288:334–341.

Arts J, Kuiper GG, Janssen JM, Gustafsson

JA, Löwik CW, Pols HA, van Leeuwen JP.

Differential expression of estrogen receptors

α and β mRNA during differentiation of

human osteoblast SV-HFO cells.

Endocrinology 1997;138:5067–5070.

Onoe Y, Miyaura C, Ohta H, Nozawa S,

Suda T. Expression of estrogen receptor β in

rat bone. Endocrinology 1997;138:4509–

Black LJ, Sato M, Rowley ER, Magee DE,

Bekele A, Williams DC, Cullinan GJ,

Bendele R, Kauffman RF, Bensch WR.

Raloxifene (LY139481 HCI) prevents bone

loss and reduces serum cholesterol without

causing uterine hypertrophy in

ovariectomized rats. J Clin Invest

;93:63–69.

Ettinger B, Black DM, Mitlak BH,

Knickerbocker RK, Nickelsen T, Genant HK,

Christiansen C, Delmas PD, Zanchetta JR,

Stakkestad J, Glüer CC, Krueger K, Cohen

FJ, Eckert S, Ensrud KE, Avioli LV, Lips P,

Cummings SR. Reduction of vertebral

fracture risk in postmenopausal women with

osteoporosis treated with raloxifene: results

from a 3-year randomized clinical trial.

JAMA 1999;282:637–645.

Pike AC, Brzozowski AM, Hubbard RE,

Bonn T, Thorsell AG, Engström O,

Ljunggren J, Gustafsson JA, Carlquist M.

Structure of the ligand binding domain of

oestrogen receptor beta in the presence of a

partial agonist and a full antagonist. EMBO J

;18:4608–4618.

Bryant HU, Glasebrook AL,Yang NN, Sato

M. An estrogen receptor basis for raloxifene

action in bone. J Steroid Biochem Mol Biol

;69:37–44.

Anderson JJB, Garner SC. The effects of

phytoestrogens on bone. Nutr Res

;20:220–224.

Messina M. Soyfoods, soybean isoflavones,

and bone health. Korean Soybean Digest

;15:122–136.

Ishida H, Uesugi T, Hirai K, Toda T, Nukaya

H, Yokotsuka K, Tsuji K. Preventive effects

of the plant isoflavones, daidzin and genistin,

on bone loss in ovariectomized rats fed a

calcium-deficient diet. Biol Pharm Bull

;21, 62–66.

Kurzer MS, Xu X. Dietary phytoestrogen.

Annu Rev Nutr 1997;17:353–381.

Mazur W, Adlercreutz H. Overview of

naturally occurring endocrineactive

substances in the human diet in relation to

human health. Nutrition 2000;16:654–658.

Arjmandi BH, Alekel L, Hollis BW, Amin

D, Stacewicz-Sapuntzakis M, Guo P,

Kukreja SC. Dietary soybean protein

prevents bone loss in an ovariectomized rat

model of osteoporosis. J Nutr 1996;126:161–

Arjmandi BH, Birnbaum R, Goyal NV,

Getlinger MJ, Juma S, Alekel L, Hasler CM,

Drum ML, Hollis BW, Kukreja S. Bonesparing effect of soy protein in ovarian

hormone-deficient rats is related to its

isoflavone content. Am J Clin Nutr 1998,

(Suppl 6):1364S–1368S.

Fanti P, Monier-Faugere MC, Geng Z,

Schmidt J, Morris PE, Cohen D, Malluche

HH. The phytoestrogen genistein reduces

bone loss in shortterm ovariectomized rats.

Osteoporos Int 1998;8:274–281.

Ishimi Y, Miyaura C, Ohmura M, Onoe Y,

Sato T, Uchiyama Y, Ito M, Wang X, Suda

T, Ikegami S. Selective effects of genistein, a

soybean isoflavone, on B-lymphopoiesis and

bone loss caused by estrogen deficiency.

Endocrinology 1999;140:1893–1900.

Picherit C, Coxam V, Bennetau-Pelissero C,

Kati-Coulibaly S, Davicco MJ, Lebecque P,

Barlet JP. Daidzein is more efficient than

genistein in preventing ovariectomy-induced

bone loss in rats. J Nutr 2000; 130:1675–

Glazier MG and Bowman MA. A review of

the evidence for use of phytoestrogens as a

replacement for traditional estrogen

replacement therapy. Arch Internal Med

; 161: 1161–1172.

Farmakalidis E, Hathcock JN, Murphy PA.

Oestrogenic potency of genistin and daidzin

in mice. Food Chem. Toxicol 1985; 23:741–

Kalu DN, Liu CC, Salerno E, Hollis B,

Echon R, Ray M. Skeletal response of

ovariectomized rats to low and high doses of

β-estradiol. Bone Miner 1991; 14:175–

Kalu DN, Masoro EJ, Byung PB, Hardin RR,

Hollis BW. Modulation of age-related

hyperparathyroidism and senile bone loss in

Fisher rats by soy protein and food

restriction. Endocrinology 1988;122:1847–

Yao W, Hadi T, Jiang Y, Lotz J, Wronski TJ,

Lane NE. Basic fibroblast growth factor

improves trabecular bone connectivity and

bone strength in the lumbar vertebral body of

osteopenic rats. Osteoporos Int

;16:1939–1947.

Lukitaningsih E: The exploration of

whitening and sun screening compounds in

bengkoang roots (Pachyrhizus erosus), Ph.D

Thesis. Wuerzburg University, Faculty of

Pharmacy and Food Chemistry; 2009.

Uesugi T, Toda T, Tsuji K, Ishida H.

Comparative study on reduction of bone loss

and lipid metabolism abnormality in

ovariectomized rats by soy isoflavones,

daidzin, genistin, and glycitin. Biol Pharm

Bull 2001; 24:368–372.

Downloads

Published

31-12-2010

How to Cite

1.
Arief Nurrochmad, Fransiska Leviana, Caecilia Govita Wulancarsari, Endang Lukitaningsih. Phytoestrogens of Pachyrhizus erosus prevent Bone Loss in an Ovariectomized Rat Model of Osteoporosis. ijp [Internet]. 2010 Dec. 31 [cited 2024 Dec. 6];2(4):363-72. Available from: https://ijp.arjournals.org/index.php/ijp/article/view/59

Issue

Section

Original Research Articles